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A bs tr ac t
Background
The RTS,S/AS malaria vaccine is being developed for delivery through the World 
Health Organization’s Expanded Program on Immunization (EPI). We assessed the 
feasibility of integrating RTS,S/AS02D into a standard EPI schedule for infants.
Methods
In this phase 2B, single-center, double-blind, controlled trial involving 340 infants 
in Bagamoyo, Tanzania, we randomly assigned 340 infants to receive three doses 
of either the RTS,S/AS02D vaccine or the hepatitis B vaccine at 8, 12, and 16 weeks 
of age. All infants also received a vaccine containing diphtheria and tetanus toxoids, 
whole-cell pertussis vaccine, and conjugated Haemophilus inf luenzae type b vaccine 
(DTPw/Hib). The primary objectives were the occurrence of serious adverse events 
during a 9-month surveillance period and a demonstration of noninferiority of the 
responses to the EPI vaccines (DTPw/Hib and hepatitis B surface antigen) with co-
administration of the RTS,S/AS02D vaccine, as compared with the hepatitis B vaccine. 
The detection of antibodies against Plasmodium falciparum circumsporozoite and effi-
cacy against malaria infection were secondary objectives.
Results
At least one serious adverse event was reported in 31 of 170 infants who received the 
RTS,S/AS02D vaccine (18.2%; 95% confidence interval [CI], 12.7 to 24.9) and in 42 of 
170 infants who received the hepatitis B vaccine (24.7%; 95% CI, 18.4 to 31.9). The 
results showed the noninferiority of the RTS,S/AS02D vaccine in terms of antibody 
responses to EPI antigens. One month after vaccination, 98.6% of infants receiving 
the RTS,S/AS02D vaccine had seropositive titers for anticircumsporozoite antibod-
ies on enzyme-linked immunosorbent assay (ELISA). During the 6-month period af-
ter the third dose of vaccine, the efficacy of the RTS,S/AS02D vaccine against first 
infection with P. falciparum malaria was 65.2% (95% CI, 20.7 to 84.7; P = 0.01).
Conclusions
The use of the RTS,S/AS02D vaccine in infants had a promising safety profile, did not 
interfere with the immunologic responses to coadministered EPI antigens, and re-
duced the incidence of malaria infection. (ClinicalTrials.gov number, NCT00289185.)
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Malaria persists as a major public health problem, and new tools for con-trol of the disease are needed to facilitate 
the current renewed commitment for its control 
or elimination.1,2 The malaria vaccine contains 
the RTS,S antigen formulated with one of two 
adjuvant systems (AS), AS01 or AS02, and targets 
the pre-erythrocytic stage of Plasmodium falciparum 
parasite. This vaccine also has the potential to 
provide protection against infection with hepati-
tis B virus, since it contains the hepatitis B surface 
antigen. Studies conducted thus far show that the 
vaccine has a promising safety profile, is immuno-
genic, and confers partial protection against in-
fection in adults who have not had malaria infec-
tion in the challenge model3,4 and in adults with 
partial immunity in the Gambia.5 A proof-of-con-
cept study in children between the ages of 1 and 
4 years in Mozambique also demonstrated protec-
tion against clinical malaria and severe disease 
lasting more than 18 months.6,7
The RTS,S/AS candidate malaria vaccine, which 
is being developed for infants and children in 
regions in sub-Saharan Africa in which malaria 
is endemic, will ideally be delivered through the 
Expanded Program on Immunization (EPI) of the 
World Health Organization. Therefore, the two 
main aims of the development plan are to dem-
onstrate prevention of malaria, which occurs in 
infants who have reached about 4 months of age 
(when maternally acquired immunity wanes8) and 
to support the inclusion of the RTS,S/AS vaccine 
in the EPI, which has successfully expanded the 
coverage of basic vaccines across the developing 
world.9
The clinical development plan for the RTS,S/
AS02D vaccine (with the letter D indicating the 
pediatric formulation) has followed a two-step ap-
proach after the proof-of-concept trial.6 As a first 
step, the vaccine was tested in infants in Mozam-
bique with a staggered administration of ma-
laria vaccine and EPI vaccines.10 This trial showed 
that the malaria vaccine candidate had a promis-
ing safety profile, was immunogenic, and con-
ferred 65% protection against malaria infection 
in infants.10 We describe the results of the coad-
ministration of this vaccine with EPI vaccines in 
infants living in an area of perennial malaria 
transmission in Tanzania.
Me thods
Study Design
This phase 2B, single-center, double-blind, con-
trolled trial was conducted between July 2006 
and February 2008 by the Bagamoyo Research and 
Training Centre, a branch of the Ifakara Health 
Institute in Bagamoyo, Tanzania. The protocol 
was approved by the Ifakara Health Institute, the 
Western Institutional Review Board in the United 
States, the National Institute of Medical Research 
in Tanzania, the Institutional Review Board of the 
London School of Hygiene and Tropical Medicine, 
and the Swiss Tropical Institute through the local 
government ethics committee in Basel, Switzer-
land. The trial was undertaken in accordance with 
the provisions of the International Conference on 
Harmonisation and Good Clinical Practice guide-
lines and was monitored by the sponsor, Glaxo-
SmithKline Biologicals, which provided both the 
RTS,S/AS02D vaccine and the hepatitis B vaccine. 
Vaccine containing diphtheria and tetanus tox-
oids, whole-cell pertussis vaccine, and conjugat-
ed Haemo philus inf luenzae type b vaccine (DTPw/
Hib) (TETRActHib) was purchased from Aventis 
Pasteur.
The design, conduct, and results of the trial 
were overseen by a formally constituted data and 
safety monitoring board, operating under a char-
ter. Written informed consent in Swahili was ob-
tained from parents of infants before study entry; 
parents who were not able to write indicated 
consent using a thumbprint, with a signature 
from a literate witness to the consent procedure. 
All authors vouch for the completeness and ac-
curacy of the data presented. For further method-
ologic details, see the Supplementary Appendix, 
available with the full text of this article at www.
nejm.org.
Study Vaccines
We randomly assigned infants to receive three 
doses of either the RTS,S/AS02D vaccine or the 
hepatitis B vaccine (Engerix-B) through intramus-
cular injection in the left anterolateral thigh and 
the DTPw/Hib vaccine through intramuscular in-
jection in the right anterolateral thigh at 8, 12, and 
16 weeks of age. Each dose of the RTS,S/AS02D 
vaccine (0.5 ml) contained 25 μg of RTS,S and 
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the adjuvant system AS02D, as described previ-
ously.11 Oral polio vaccine was provided and ad-
ministered at birth with sequential doses of 
DTPw/Hib.
Safety Assessments
After each vaccination, infants were observed for 
1 hour for general adverse events. Trained field 
workers visited the children at home every day for 
the following 6 days to record solicited reports of 
adverse events. Unsolicited reports of adverse 
events were recorded for 30 days after each dose, 
and serious adverse events were recorded through-
out the study with the use of the morbidity sur-
veillance system in place at Bagamoyo District 
Hospital. In addition, all enrolled infants were 
visited monthly at home by field workers to max-
imize identification of serious adverse events. As 
part of safety monitoring at the initial screening, 
at 1 week after the first dose of a study vaccine, 
and at 1 month after the third dose, we measured 
hemoglobin, hematocrit, platelets, and white cells, 
along with creatinine for assessment of renal 
function and alanine aminotransferase and bili-
rubin for assessment of hepatic function. The in-
tensity of symptoms was graded on a scale of 0 to 
3, with higher scores indicating greater intensity. 
Grade 3 symptoms were defined as crying when 
the limb was moved or a spontaneously painful 
limb (local pain), injection-site redness or swell-
ing measuring more than 20 mm in diameter, an 
axillary temperature of more than 39.0°C, or other 
symptoms preventing normal daily activities (for 
details, see the Supplementary Appendix).
Monitoring for Clinical Malaria Episodes
Surveillance for malaria infections by P. falciparum 
was undertaken by both active detection of infec-
tion and passive case detection. Any infant pre-
senting with a documented fever (axillary temper-
ature, ≥37.5°C) within the preceding 24 hours 
underwent a blood draw for the determination of 
malaria parasites. For active detection of infec-
tion, home visits were conducted every 2 weeks 
after the administration of the third dose of a 
study vaccine. Four weeks before the start of sur-
veillance for malaria infection (i.e., 2 weeks be-
fore the third dose), asymptomatic parasitemia 
was cleared with artemether–lumefantrine, with 
the dose determined according to body weight. 
Each infant received a total of six doses of this 
drug during a 3-day period. The absence of para-
sitemia was confirmed by the analysis of a blood 
sample obtained 2 weeks later. Infants who con-
tinued to have parasitemia were retreated and 
excluded from the analysis. (For further details 
regarding the active detection of infection and 
determination of parasitemia, see the Supplemen-
tary Appendix.)
Laboratory Analysis
Antibody titers for anticircumsporozoite and anti–
hepatitis B surface antigen were determined at 
screening and 1 month after the second and third 
doses of vaccine. Antibodies against diphtheria 
and tetanus toxins, polyribosylribitol phosphate 
for Hib, and Bordetella pertussis were measured at 
baseline and 1 month after the third dose of vac-
cine. The noninferiority of responses to hepatitis 
B, diphtheria, tetanus, Hib, and whole-cell pertus-
sis were determined 1 month after the third dose 
(see the Supplementary Appendix for details).
Statistical Analysis
The analysis was based on a prospectively de-
fined report and analysis plan. The primary end 
point for safety was the occurrence of serious 
adverse events during the first 9 months of the 
study in the intention-to-treat population, which 
included all infants for whom data were avail-
able. The primary end point of immunogenicity 
was the demonstration of noninferiority with re-
spect to antibody responses to all antigens in the 
EPI vaccines at 1 month after the third dose of 
vaccine. This analysis was conducted in the per-
protocol population for immunogenicity, which 
included all infants who could be evaluated — in 
other words, those who met all eligibility criteria, 
who had full compliance with the procedures (as 
defined in the protocol), who had no elimination 
criteria during the study, and for whom data con-
cerning immunogenicity end-point measures were 
available. Noninferiority criteria were predefined 
and set to exclude more than a 10% decrease in 
protective antibody levels to diphtheria, tetanus, 
Hib, and hepatitis B surface antigen or to rule out 
a decrease by more than a factor of 1.5 in average 
antibody titers to whole-cell pertussis after vac-
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cination. Secondary end points included further 
analyses of safety, reactogenicity, and immuno-
genicity and an estimation of vaccine efficacy 
against incident infections.
Vaccine efficacy was estimated for the per-
protocol population (for details, see the Supple-
mentary Appendix). Cases of infection were first 
or only infections with asexual P. falciparum, as 
detected by either active or passive means during 
the follow-up period, starting 14 days after the 
third dose of a study vaccine and continuing for 
approximately 7 months. The study evaluated ef-
ficacy against clinical malaria, which had a pri-
mary case definition of fever (axillary tempera-
ture, ≥37.5°C) with an asexual parasitemia of 500 
parasites per microliter or more as an explor-
atory end point. This case definition had a re-
ported sensitivity and specificity of more than 
90%.12 A secondary case definition for clinical 
malaria included fever or a history of fever in the 
previous 24 hours plus any asexual P. falciparum 
parasitemia. The measure of person-years at risk 
was adjusted for absences from the study area and 
for the use of antimalarial drugs. Estimates of 
vaccine efficacy for the intention-to-treat popu-
lation included all infants who had received at 
least one dose of a study vaccine. Measurement 
of the time at risk started at the administration 
of the first dose. Time at risk was not corrected 
for absences or for the use of antimalarial drugs.
Vaccine efficacy was defined as 1 minus the 
hazard ratio and was adjusted according to the 
village of residence and the distance to Baga-
moyo District Hospital. The adjusted vaccine ef-
ficacy was assessed with the use of Cox regres-
sion models.
The sample size of 170 infants per study group 
was calculated to have a power of 90% to reach 
the noninferiority of the RTS,S/AS02D vaccine, 
as compared with the hepatitis B vaccine, with 
respect to EPI antigen responses after vaccina-
tion. The trial also had a power of 80% to detect 
a difference of 7 to 13% between the two study 
groups in reports of serious adverse events (for 
varying rates in the control subjects) and a power 
of more than 90% to detect a significant vaccine 
efficacy under the assumption of an attack rate 
of 50% in control subjects and of 45% true vac-
cine efficacy. A two-sided P value of less than 0.05 
was considered to indicate statistical significance.
R esult s
Subjects
The first mother was screened on July 21, 2006. The 
first infant was enrolled on September 27, 2006, 
and the last infant was enrolled on May 4, 2007. 
A total of 378 infants were screened, and 340 were 
vaccinated with the first dose of a study vaccine 
(Fig. 1). The same number of infants in each 
study group (153) completed the final study visit 
at 9 months.
The demographic profiles of the group receiv-
ing the RTS,S/AS02D vaccine and the group re-
ceiving the hepatitis B vaccine in the intention-to-
treat population were balanced in terms of sex, 
mean age, and distance from the health center 
(Table 1). The mean age of infants when they re-
ceived the first dose of a study vaccine was 7.8 
weeks.
Safety and Reactogenicity
From the time of the first vaccination until 9 months 
after the first dose, at least one serious adverse 
event was reported in 31 of 170 infants receiving 
the RTS,S/AS02D vaccine (18.2%; 95% confidence 
interval [CI], 12.7 to 24.9) and in 42 of 170 infants 
receiving the hepatitis B vaccine (24.7%; 95% CI, 
18.4 to 31.9) (Table 2). When serious adverse 
events caused by malaria were excluded, similar 
numbers of subjects in the two groups reported 
serious adverse events: 29 receiving the RTS,S/
AS02D vaccine (17.1%) and 40 receiving the hepa-
titis B vaccine (23.5%).
Pneumonia was the most frequently reported 
serious adverse event in both groups, occurring 
in 10 infants receiving the RTS,S/AS02D vaccine 
(5.9%; 95% CI, 2.9 to 10.6) and in 28 infants re-
ceiving the hepatitis B vaccine (16.5%; 95% CI, 
11.2 to 22.9) (P = 0.003). The next two most fre-
quently reported serious adverse events were ane-
Figure 1 (facing page). Enrollment and Outcomes.
Because of unavailability of vaccine at the study site, 
some infants who received the first dose of a study vac-
cine did not receive the second dose, the third dose, or 
both doses. Six recipients of the RTS,S/AS02D vaccine 
and five recipients of the hepatitis B vaccine received in-
complete vaccination but were included in the 9-month 
follow-up. EPI denotes Expanded Program on Immuni-
zation.
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33p9
340 Underwent randomization
378 Infants were screened
17 Did not have access to EPI vaccine
11 Did not meet eligibility criteria
5 Were too late for enrollment
3 Could not have blood drawn
2 Withdrew consent 
170 Were assigned to receive
RTS,S/AS02D vaccine
170 Were assigned to receive
hepatitis B vaccine
2 Moved
1 Withdrew consent
2 Did not receive doses 2 and 3
1 Moved
2 Withdrew consent
4 Did not receive doses 2 and 3
163 Received second dose 165 Received second dose
170 Received first dose 170 Received first dose
2 Withdrew consent
2 Did not receive dose 3
1 Withdrew consent
3 Did not receive dose 3
151 Were included in the 
immunogenicity analysis   
3 Had underlying medical
condition
4 Were noncompliant with
vaccination schedule
1 Was noncompliant with
blood sampling schedule
156 Were included in the
immunogenicity analysis   
5 Were noncompliant with
vaccination schedule
146 Were included in the efficacy
analysis
3 Had underlying medical
condition
4 Were noncompliant with
vaccination schedule
6 Had no follow-up data
151 Were included in the efficacy
analysis
5 Were noncompliant with
vaccination schedule
5 Had no follow-up data
5 Were lost to follow-up
4 Moved
3 Withdrew consent
3 Were lost to follow-up
7 Moved
2 Withdrew consent
1 Died
153 Completed 9-mo visit 153 Completed 9-mo visit
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Table 2. Incidence of Serious Adverse Events, Unsolicited Reports of Adverse Events, and Solicited Reports of Injection-Site 
and General Adverse Events (Intention-to-Treat Population).*
Event Hepatitis B Vaccine RTS,S/AS02D Vaccine
No.
Percent 
(95% CI) No.
Percent
(95% CI)
Serious adverse event†
Total no. of subjects 170 170
No. of subjects with event
Any 42 24.7 (18.4–31.9) 31 18.2 (12.7–24.9)
Plasmodium falciparum infection 7 4.1 (1.7–8.3) 2 1.2 (0.1–4.2)
In absence of P. falciparum infection 40 23.5 (17.4–30.6) 29 17.1 (11.7–23.6)
Pneumonia 28 16.5 (11.2–22.9) 10 5.9 (2.9–10.6)
Gastroenteritis 5 2.9 (1.0–6.7) 8 4.7 (2.1–9.1)
Anemia 8 4.7 (2.1–9.1) 2 1.2 (0.1–4.2)
Death‡ 1 0.6 (0.0–3.2) 0 0 (0.0–2.1)
Unsolicited report of adverse event§
No. of subjects with event
Any 141 82.9 (76.4–88.3) 137 80.6 (73.8–86.2)
Cough 80 47.1 (39.4–54.9) 80 47.1 (39.4–54.9)
Pneumonia 54 31.8 (24.8–39.3) 49 28.8 (22.1–36.3)
Rhinorrhea 73 42.9 (35.4–50.7) 56 32.9 (25.9–40.6)
Severity grade 3 16 9.4 (5.5–14.8) 7 4.1 (1.7–8.3)
Related to vaccine 2 1.2 (0.1–4.2) 0 0 (0.0–2.1)
mia (in two infants receiving the RTS,S/AS02D 
vaccine and in eight receiving the hepatitis B vac-
cine) and gastroenteritis (in eight infants receiv-
ing the RTS,S/AS02D vaccine and in five infants 
receiving the hepatitis B vaccine). All other seri-
ous adverse events occurred infrequently. One 
serious adverse event was fatal: a case of severe 
pneumonia and symptomatic seizures in an in-
fant receiving the hepatitis B vaccine. Observers 
who were unaware of study-group assignments 
determined that none of the serious adverse 
events were related to vaccination.
Solicited reports of pain and swelling at the 
injection site occurred with a similar incidence in 
the two study groups (Table 2). No solicited re-
ports of grade 3 injection-site symptoms were 
reported after the administration of either study 
vaccine. In comparison, the local reactogenicity 
associated with the DTPw/Hib vaccine was 85.0% 
of doses that were followed by pain and 3.8% of 
doses that were followed by swelling.
Table 1. Demographic Characteristics of the Subjects (Intention-to-Treat 
Population).*
Characteristic
Hepatitis B 
Vaccine 
(N = 170)
RTS,S/AS02D
Vaccine 
(N = 170)
All  
Subjects 
(N = 340)
Age at the time of first dose  
of vaccine — wk
7.9±0.8 7.8±0.8 7.8±0.8
Sex — no. (%)
Female 85 (50.0) 91 (53.5) 176 (51.8)
Male 85 (50.0) 79 (46.5) 164 (48.2)
Distance from hospital to home  
— km
<5.0 59 (34.7) 45 (26.5) 104 (30.6)
5.0–9.9 16 (9.4) 20 (11.8) 36 (10.6)
10.0–14.9 42 (24.7) 51 (30.0) 93 (27.4)
≥15.0 53 (31.2) 54 (31.8) 107 (31.5)
* Plus–minus values are means ±SD. Percentages may not total 100 because of 
rounding.
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Among solicited reports, fever (axillary tem-
perature, ≥37.5°C) and irritability were the most 
frequently reported general symptoms in the two 
vaccine groups (Table 2). Fever was reported more 
frequently after the administration of the RTS,S/
AS02D vaccine with DTPw/Hib than after the 
administration of the hepatitis B vaccine with 
DTPw/Hib (29.6% and 13.6%, respectively). Most 
fevers were grade 1 or grade 2 in intensity (<39°C); 
only one grade 3 fever (≥39°C) was reported, 
after the third dose of hepatitis B vaccine.
Irritability, drowsiness, and loss of appetite 
were recorded after similar proportions of doses 
of the two vaccines; none of these symptoms 
were grade 3 in intensity.
During the first 30 days after vaccination, un-
Table 2. (Continued.)
Event Hepatitis B Vaccine RTS,S/AS02D Vaccine
No.
Percent 
(95% CI) No.
Percent
(95% CI)
Solicited report of adverse event
Total no. of doses 492 490
Injection-site reaction
Pain
Any 416 84.6 (81.1–87.6) 416 84.9 (81.4–88.0)
Severity grade 3 0 0 (0.0–0.7) 0 0 (0.0–0.8)
Swelling
Any 18 3.7 (2.2–5.7) 19 3.9 (2.4–6.0)
Severity grade 3 0 0 (0.0–0.7) 0 0 (0.0–0.8)
General
Drowsiness
Any¶ 4 0.8 (0.2–2.1) 3 0.6 (0.1–1.8)
Related to vaccine 2 0.4 (0.0–1.5) 0 0 (0.0–0.8)
Irritability
Any¶ 96 19.5 (16.1–23.3) 112 22.9 (19.2–26.8)
Related to vaccine 94 19.1 (15.7–22.9) 109 22.2 (18.6–26.2)
Loss of appetite
Any¶ 5 1.0 (0.3–2.4) 5 1.0 (0.3–2.4)
Related to vaccine 3 0.6 (0.1–1.8) 2 0.4 (0.0–1.5)
Fever‖
Any 67 13.6 (10.7–17.0) 145 29.6 (25.6–33.9)
Severity grade 3 1 0.2 (0.0–1.1) 0 0 (0.0–0.8)
Related to vaccine 62 12.6 (9.8–15.9) 144 29.4 (25.4–33.6)
Severity grade 3 and related to vaccine 1 0.2 (0.0–1.1) 0 0 (0.0–0.8)
* Subjects could have more than one adverse event.
† For serious adverse events, the four most frequently reported events and all deaths are listed.
‡ One infant died of pneumonia and symptomatic seizures.
§ For all adverse events, those occurring in more than 10% of subjects in any group and those related to a study vaccine 
are listed.
¶ No grade 3 adverse events were reported.
‖ Fever was defined as an axillary temperature of 37.5°C or greater.
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solicited reports of symptoms occurred in 80.6% 
of infants receiving the RTS,S/AS02D vaccine 
and in 82.9% of those receiving the hepatitis B 
vaccine (Table 2); the most common symptoms 
were cough (47.1% in both groups), rhinorrhea 
(32.9% and 42.9%, respectively), and pneumonia 
(28.8% and 31.8%, respectively). There was a 
trend toward a higher incidence of rash in re-
cipients of the RTS,S/AS02D vaccine (7.1%; 95% 
CI, 3.7 to 12.0) than in recipients of the hepa-
titis B vaccine (0.6%; 95% CI, 0 to 3.2); none of 
these events were of severity grade 3. There was 
no other imbalance in other adverse events be-
tween the two study groups, and all events were 
those expected for the population. Two infants 
receiving the hepatitis B vaccine had an unsolic-
ited report of an adverse event that was consid-
ered to be related to a study vaccine: injection-
site erythema of moderate intensity and rash of 
mild intensity. Unsolicited reports of grade 3 
events were infrequent and occurred in similar 
proportions in recipients of the RTS,S/AS02D vac-
cine and hepatitis B vaccine (4.1% and 9.4%, re-
spectively). The most frequently reported grade 3 
adverse event was pneumonia (2.4% and 6.5%, 
respectively).
Only 12 hematologic or biochemical values 
were outside the acceptable range in the two study 
groups. The abnormalities, which were all of 
grade 1 toxicity, included six tests of hemoglobin 
(in four recipients of the RTS,S/AS02D vaccine 
and in two recipients of the hepatitis B vaccine) 
and one test of alanine aminotransferase in a re-
cipient of hepatitis B vaccine 1 week after the first 
dose and four tests of hemoglobin (one in a re-
cipient of the RTS,S/AS02D vaccine and three in 
recipients of the hepatitis B vaccine) and one test 
of the white-cell count in a recipient of the RTS,S/
AS02D vaccine 1 month after the third dose.
Immunogenicity Results
Noninferiority of the humoral responses to all EPI 
antigens was demonstrated in a comparison of 
the RTS,S/AS02D vaccine with the hepatitis B vac-
cine coadministered with DTPw/Hib, as indicated 
by the value of −10 or more for the lower limit of 
the 95% confidence interval of difference in sero-
protection rates or a value of more than 0.66 for 
the ratio of geometric mean titers between the two 
groups. Rates of seroprotection and seropositiv-
ity were high for all antigens (>94%) (Table 3).
Before vaccination, the prevalence of mater-
nally transferred antibodies against EPI antigens 
was relatively high, except for B. pertussis; however, 
geometric mean titers were low. After the full 
vaccination course, geometric mean titers for EPI 
antigens (apart from antibodies to hepatitis B 
surface antigen) tended to be lower among in-
fants receiving the RTS,S/AS02D vaccine than 
among those receiving the hepatitis B vaccine. In 
the intention-to-treat population, 14 infants (4.1%) 
— 4 receiving the RTS,S/AS02D vaccine and 10 
receiving the hepatitis B vaccine — did not reach 
seroprotective concentrations for all EPI antigens. 
All these children were revaccinated with the re-
spective antigens.
At baseline, 33 of 141 children (23.4%) receiv-
ing the RTS,S/AS02D vaccine and 39 of 152 chil-
dren (25.7%) receiving the hepatitis B vaccine 
were seropositive for anticircumsporozoite anti-
bodies (≥0.5 enzyme-linked immunosorbent as-
say [ELISA] units per milliliter) with low titers 
(Table 3). One month after administration of the 
third dose of a study vaccine, 141 of 143 of in-
fants (98.6%) receiving the RTS,S/AS02D vaccine 
were seropositive for anticircumsporozoite anti-
bodies (geometric mean titer, 69.5; 95% CI, 53.9 
to 89.6), as compared with 2 infants receiving 
the hepatitis B vaccine (1.4%). All infants receiv-
ing the RTS,S/AS02D vaccine were seroprotected 
against hepatitis B, as compared with 94.3% of 
those receiving the hepatitis B vaccine.
Efficacy
After the administration of the third dose of a 
study vaccine, 28 incident malaria infections in-
volving the detection of any level of parasitemia 
were reported in the two study groups between 
day 14 and approximately 7 months (Table 4). Dur-
ing this period, the incidence of the first malaria 
infection was 0.12 per person-year in infants re-
ceiving the RTS,S/AS02D vaccine and 0.29 per 
person-year in those receiving the hepatitis B vac-
cine. The crude vaccine efficacy against infection 
was 60.6% (95% CI, 10.4 to 82.6; P = 0.03), which 
increased to 65.2% (95% CI, 20.7 to 84.7; P = 0.01) 
after adjustment for the subject’s area of residence 
and distance from the health center. Figure 2 
shows Kaplan–Meier curves of the cumulative in-
cidence of first malaria infections in the two 
study groups.
The adjusted rates of vaccine efficacy were 
58.6% (95% CI, −1.8 to 83.2) for the incidence of 
febrile malaria (the first or only episode of axil-
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lary fever of ≥37.5°C or a history of fever and any 
parasitemia) and 43.2% (95% CI, −47.1 to 78.0) 
for febrile malaria with a parasite-density thresh-
old of more than 500 per microliter. Vaccine ef-
ficacy against febrile malaria (first or only epi-
sode of axillary fever of >37.5°C or a history of 
fever and any parasitemia) in the intention-to-
treat population from first vaccination was 41.8% 
(95% CI, −32.9 to 74.6; P = 0.20). Exploration of 
the relationship between antibody titers and the 
risk of infection showed that a doubling of anti-
circumsporozoite titers corresponded to a 16% 
reduction in the risk of infection and that there 
was a significant difference in titers between 
infants receiving the RTS,S/AS02D vaccine who 
were not infected and those who were infected 
(74.8 vs. 17.8 ELISA units per milliliter, P = 0.03).
Discussion
In our trial, the use of the RTS,S malaria vaccine, 
formulated in the AS02 adjuvant system, when 
coadministered to infants with other routinely 
delivered EPI immunizations, did not pose any 
obvious safety concerns and did not interfere with 
the immunogenicity of the multiple coadminis-
tered antigens. The results are in keeping with 
those of a trial in which the administration of 
the RTS,S/AS02D vaccine to Mozambican infants 
was staggered with EPI vaccinations.10 Low-grade 
fever was reported more frequently in infants re-
ceiving the RTS,S/AS02D vaccine (29.6%) than in 
the control group receiving the hepatitis B vaccine 
(13.6%). There were no cases of high-grade fever 
in infants receiving the RTS,S/AS02D vaccine, and 
there was no significant difference in the number 
of other solicited and unsolicited reports of ad-
verse events between the two study groups. Since 
hospitalizations for pneumonia were more com-
mon in the control group, the malaria vaccine 
candidate may reduce important indirect conse-
quences of malaria.
At the time of the first vaccination, about 25% 
of the infants were seropositive with low concen-
trations of anticircumsporozoite antibodies, which 
were probably acquired transplacentally. After 
3 months, the anticircumsporozoite antibodies 
had almost disappeared in the control group but 
were higher in almost all RTS,S/AS02D vaccine 
recipients. The concentrations of the anticircum-
sporozoite titer in our study were lower than 
those observed in the staggered administration T
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and among children between the ages of 1 and 
4 years,6,10 which suggests that the EPI vaccines 
may have interfered with the anticircumsporo-
zoite responses but had not prevented the confer-
ring of protection. These data suggest an associa-
tion between the level of anticircumsporozoite 
antibody titer and the risk of P. falciparum infec-
tion, in keeping with previous studies that have 
found a relationship between the level of anti-
circumsporozoite antibodies and efficacy against 
infection but not against clinical episodes.6,10 The 
response induced to hepatitis B surface antigen 
by the RTS,S/AS02D vaccine was higher than that 
of the licensed vaccine.
We also evaluated the feasibility of incorporat-
ing the RTS,S/AS02D vaccine into the standard 
EPI vaccination schedule in terms of immunoge-
nicity. Our study followed a previous trial10 in 
which either the RTS,S/AS02D vaccine or the 
hepatitis B vaccine was given, staggered with the 
same DTPw/Hib vaccine that we used in our trial. 
Responses to antigens in the EPI vaccines were 
similar in the two comparator groups in which 
DTPw/Hib vaccine was administered either alone 
or in combination with hepatitis B vaccine. The 
geometric mean titers and seroprotection rates 
were broadly similar between a group receiving 
simultaneous administration of the EPI vaccines 
and a group receiving delayed (by 2 weeks) ad-
ministration, with seroprotection rates of 100% 
in the latter group for diphtheria, tetanus, pertus-
sis, and Hib and of 98.5% for hepatitis B surface 
antigen.
Criteria of noninferiority for all EPI antigens 
were predefined in the protocol. Although respons-
es that were induced to most components of the 
DTPw/Hib vaccine were slightly lower for infants 
receiving the RTS,S/AS02D vaccine than for those 
receiving the hepatitis B vaccine, seroprotective 
levels for both groups and all antigens were high, 
and all noninferiority criteria were met.
In an earlier trial of the RTS,S vaccine in 
children,6 efficacy against breakthrough infec-
tions was associated with reductions in both mild 
and severe malaria episodes. The rate of protec-
tion of 65% against new infections that we 
observed is encouraging and is similar to the 
observations in the earlier trial with staggered 
administration in Mozambican infants.10 How-
ever, rates of infection were substantially lower 
in our trial, and the finding of the previous trial 
with respect to efficacy against febrile episodes 
was not confirmed.
The low rate of detection of infection through 
active surveillance is likely to be a result of im-
proved malaria control associated with distribu-
tion of bed nets, along with the close follow-up 
and improved clinical care of the infants our in 
study. Given that the infants in this trial had the 
best access to existing preventive tools and treat-
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 during the Study.
Starting 14 days after the administration of the third dose of a study vaccine through 6 months, the incidence of the 
first malaria infection was 0.12 per person-year in infants receiving the RTS,S/AS02D vaccine and 0.29 per person-year 
in those receiving the hepatitis B vaccine. The P value was calculated by the log-rank test.
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ment of malaria in Tanzania, these results indi-
cate the added benefit of a malaria vaccine within 
an integrated approach for the control and elimi-
nation of malaria.
Further development of the RTS,S/AS vaccine 
in a large phase 3 trial is warranted. If licensed 
and recommended for inclusion in the EPI sched-
ule, the RTS,S/AS vaccine could become an effec-
tive component of an integrated strategy to con-
trol malaria.
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